로딩 중…
지수 로딩 중…
10x Genomics, Inc.
TXG· NASDAQ· Health Care· Health Care Equipment & Services
$70.11-14.03%
2026-10-30
Financials
Valuation Metrics
10x Genomics, Inc.'s Market Cap is $8.90B. At end of 2025 it was $2.07B. Ranked #898 of 3,116 in US market (top 29%), #280 of 1,472 on NASDAQ (top 19%), #69 of 203 in Health Care Equipment & Services (top 34%) by Market Cap.
Investment Metrics(as of 2026-10-30)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | $8.90B | US#898/3,116 Sec#69/203 |
| Revenue | $617M | US#2,145/3,116 Sec#134/203 |
| Net Income | $-75M | US—/3,116 Sec—/203 |
| Total Assets | $1.03B | US#2,457/3,116 Sec#130/203 |
| Net Assets | $826M | US#1,890/3,116 Sec#102/203 |
| Value | ||
| P/B | 10.78x | US#2,678/3,116 Sec#174/203 |
| P/S | 14.43x | US#2,815/3,116 Sec#192/203 |
| EV/EBITDA | 302.69x | US#2,488/3,116 Sec#143/203 |
| FCF Yield | 1.36% | US#2,147/3,116 Sec#128/203 |
| Profitability | ||
| ROE | -9.10% | US#2,342/3,116 Sec#134/203 |
| ROA | -7.29% | US#2,593/3,116 Sec#149/203 |
| Op. Margin | -14.33% | US#2,547/3,116 Sec#162/203 |
| Revenue Growth | -4.28% | US#2,406/3,116 Sec#182/203 |
| Financial Health | ||
| Debt Ratio | 24.77% | US#272/3,116 Sec#26/203 |
| Total Debt | $79M | US#2,489/3,116 Sec#144/203 |
| FCF | $121M | US#1,652/3,116 Sec#96/203 |
| Cash | $503M | US#1,067/3,116 Sec#62/203 |
| Current Ratio | 5.69x | US#406/3,116 Sec#31/203 |
| Net Debt/EBITDA | -15.13x | US#26/3,116 Sec#3/203 |
| Performance | ||
| 1Y Return | 463.55% | US#5/3,116 Sec#1/203 |
| 1M Return | -22.42% | US#2,541/3,116 Sec#184/203 |
| From 52W High | -31.81% | US#1,559/3,116 Sec#132/203 |
| 1Y MDD | -28.64% | US#1,208/3,116 Sec#55/203 |
| Trading | ||
| Volume | 4,814,681 shares | US#982/3,116 Sec#49/203 |
| Trading Value | $342M | US#682/3,116 Sec#55/203 |
| Per Share | ||
| EPS | $-0.59 | US—/3,116 Sec—/203 |
| BPS | $6.50 | US#2,138/3,116 Sec#132/203 |